Sistema de Salut de Catalunya
Institut Català de la Salut
[Passaro A] Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy. [Addeo A] University Hospital of Geneva Department of Oncology, Geneva, Switzerland. [Von Garnier C] Department of Pulmonary Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. [Blackhall F] Division of Cancer Sciences, University of Manchester & The Christie NHS Foundation Trust, Manchester, UK. [Planchard D] Department of Medical Oncology, Thoracic Unit, Gustave Roussy, Villejuif, France. [Felip E] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-09-23T09:03:19Z
2021-09-23T09:03:19Z
2020-06-23
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer de pulmó
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer de pulmón
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Lung cancer
The COVID-19 pandemic, characterised by a fast and global spread during the first months of 2020, has prompted the development of a structured set of recommendations for cancer care management, to maintain the highest possible standards. Within this framework, it is crucial to ensure no disruption to essential oncological services and guarantee the optimal care. This is a structured proposal for the management of lung cancer, comprising three levels of priorities, namely: tier 1 (high priority), tier 2 (medium priority) and tier 3 (low priority)—defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and Magnitude of Clinical Benefit Scale. The manuscript emphasises the impact of the COVID-19 pandemic on lung cancer care and reconsiders all steps from diagnosis, staging and treatment. These recommendations should, therefore, serve as guidance for prioritising the different aspects of cancer care to mitigate the possible negative impact of the COVID-19 pandemic on the management of our patients. As the situation is rapidly evolving, practical actions are required to guarantee the best patients’ treatment while protecting and respecting their rights, safety and well-being. In this environment, cancer practitioners have great responsibilities: provide timely, appropriate, compassionate and justified cancer care, while protecting themselves and their patients from being infected with COVID-19. In case of shortages, resources must be distributed fairly. Consequently, the following recommendations can be applied with significant nuances, depending on the time and location for their use, considering variable constraints imposed to the health systems. An exceptional flexibility is required from cancer caregivers.
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Article
Versió publicada
Anglès
Pulmons - Càncer - Tractament; COVID-19 (Malaltia); DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms; Other subheadings::Other subheadings::/therapy; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares; Otros calificadores::Otros calificadores::/terapia; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
BMJ
ESMO Open;5
https://doi.org/10.1136/esmoopen-2020-000820
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3440]
